A new study in @JAMAOnc, led by @LovaSunMD & @CharuAggarwalMD, suggests that a 2-year immunotherapy duration is reasonable for advanced #lungcancer, and indefinite immunotherapy is not associated with improved survival. #NSCLC #ASCO23 t.co/sYzlhR39to
https://twitter.com/PennMedicine/status/1665344401067978753
Posted on Twitter/X ·
10
10
10
10
Suggested Credits
Credits on Gondola describe each credited role and may be incomplete. A brand or featured person is not necessarily the creator.